Literature DB >> 18274709

Dysmetabolic changes associated with HCV: a distinct syndrome?

Amedeo Lonardo1, Paola Loria, Nicola Carulli.   

Abstract

Although not associated with the metabolic syndrome, HCV is linked with impaired insulin signalling, insulin resistance, hypocholesterolemia and steatosis which represent a distinct HCV-associated dysmetabolic syndrome. Insulin resistance affects the development of diabetes, fibrosis, impaired response to antivirals and perhaps hepatocellular carcinoma risk. HCV infection is associated with hypocholesterolemia and steatosis reversible after sustained virologic response. A "viral", and a "metabolic" steatosis exist as function of viral genotypes. Little is known about the possible role of HCV in further components of the metabolic syndrome such as atherosclerosis, obesity, arterial hypertension, hyperuricemia and thrombotic risk factors.

Entities:  

Mesh:

Year:  2008        PMID: 18274709     DOI: 10.1007/s11739-008-0127-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  122 in total

1.  Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan.

Authors:  Kuan-Fu Liao; Chen-Yuang Peng; Shih-Wei Lai; Wu-Long Chang; Nan-Yung Hsu
Journal:  South Med J       Date:  2006-04       Impact factor: 0.954

2.  NAFLD and hyperinsulinemia are major determinants of serum ferritin levels.

Authors:  Shira Zelber-Sagi; Dorit Nitzan-Kaluski; Zamir Halpern; Ran Oren
Journal:  J Hepatol       Date:  2006-11-07       Impact factor: 25.083

3.  Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.

Authors:  E Durante-Mangoni; R Zampino; A Marrone; M-F Tripodi; L Rinaldi; L Restivo; M Cioffi; G Ruggiero; L E Adinolfi
Journal:  Aliment Pharmacol Ther       Date:  2006-11-01       Impact factor: 8.171

4.  Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection.

Authors:  S Caronia; K Taylor; L Pagliaro; C Carr; U Palazzo; J Petrik; S O'Rahilly; S Shore; B D Tom; G J Alexander
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

5.  Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.

Authors:  Silvia Mirandola; Stefano Realdon; Jahangir Iqbal; Martina Gerotto; Francesca Dal Pero; Gladis Bortoletto; Moira Marcolongo; Alessandro Vario; Christian Datz; M Mahmood Hussain; Alfredo Alberti
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

Review 6.  Cardiovascular risk in the spectrum of type 2 diabetes mellitus.

Authors:  Intekhab Ahmed; Barry J Goldstein
Journal:  Mt Sinai J Med       Date:  2006-09

Review 7.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 8.  Insulin resistant states and insulin signaling.

Authors:  Peter Vollenweider
Journal:  Clin Chem Lab Med       Date:  2003-09       Impact factor: 3.694

9.  Risk factors for cardiovascular disease after renal transplantation.

Authors:  J M Díaz; Z Sainz; L L Guirado; F Ortiz-Herbener; M Picazo; R Garcia-Camin; J Palou; A Alcaraz; R Solà
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

10.  Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin.

Authors:  A M Stanzial; G Benoni; L Cuzzolin; G B Gabrielli; M Pasino; P Perfetti; R Corrocher
Journal:  J Chemother       Date:  2003-12       Impact factor: 1.714

View more
  7 in total

1.  Adenovirus infection results in alterations of insulin signaling and glucose homeostasis.

Authors:  Shaoning Jiang; Tatyana A Gavrikova; Alexander Pereboev; Joseph L Messina
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-04-13       Impact factor: 4.310

Review 2.  Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.

Authors:  Rossana M Calderon; Luigi X Cubeddu; Ronald B Goldberg; Eugene R Schiff
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

3.  A complex signaling network involving protein kinase CK2 is required for hepatitis C virus core protein-mediated modulation of the iron-regulatory hepcidin gene expression.

Authors:  Pelagia Foka; Alexios Dimitriadis; Eleni Kyratzopoulou; Dionysios A Giannimaras; Stefania Sarno; George Simos; Urania Georgopoulou; Avgi Mamalaki
Journal:  Cell Mol Life Sci       Date:  2014-04-10       Impact factor: 9.261

Review 4.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

5.  Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES.

Authors:  Shari S Rogal; Peng Yan; David Rimland; Vincent Lo Re; Hind Al-Rowais; Linda Fried; Adeel A Butt
Journal:  Dig Dis Sci       Date:  2015-11-02       Impact factor: 3.199

Review 6.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

7.  Statin efficacy in the treatment of hepatitis C genotype I.

Authors:  Ahmad Shavakhi; Mohamad Minakari; Afshin Bighamian; Sina Sadeghian; Sara Shavakhi; Naser Khamisi; Mahsa Khodadustan; Majid Talebi; Behrooz Ataei
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.